CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM.

CGP-53353 (DAPH-7) is a selective inhibitor of PKCβII with IC50 of 0.41 uM, shows weak activity on PKCβI with IC50 of 3.8 uM.

CGP37849 is a potent, selective and competitive NMDA receptor antagonist (Ki = 35 nM). Anticonvulsive following oral administration in vivo.

CFM-4.16 is a CARP-1 functional mimetic (CFM) compound bind with CARP-1, stimulates CARP-1 expression and apoptosis.

CFM-2 is a selective non-competitive AMPAR antagonist.

CFI-401980 is a potent, selective, novel class TTK (Tyrosine Threonine Kinase) inhibitor with Ki of 0.8 nM, HCT116 GI50 of 13 nM.

CFI02 (CFI-02) is a specific inhibitor of human cytomegalovirus (HCMV) glycoprotein B-mediated fusion with IC50 of 40 nM against laboratory adapted HCMV strain AD169.

Cevipabulin, also known as TTI-237, an antimicrotubule agent, is a small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity.

Cephradine is a semi-synthetic cephalosporin antibiotic.

CEP-7055 is a potent, orally active, pan inhibitor of VEGFR, CEP-7055 is the dimethylglycine ester prodrug of CEP-5214, which inhibits human VEGFR2/KDR kinase, VEGFR1/FLT-1 kinase, and VEGFR3/FLT-4 kinase with IC50 of 18 nM, 12 nM, and 17 nM.

CEP-32496 Hcl is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

CEP-1347 (KT-7515) is a potent and selective MLK inhibitor that completely rescues motoneurons and inhibits JNK1 activation with IC50 of 20 nM.

Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

Centanafadine (hydrochloride) is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM).

Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM.

CeMMEC2 is a novel potent BRD4 inhibitor with IC50 of 0.9 uM, binds to both bromodomains of BRD4, comparably to (S)-JQ1..

Cell permeable fluoromethyl ketone (FMK)-derivatized peptides act as effective irreversible Caspase inhibitors with no cytotoxic effects and, therefore, are useful tools for studying Caspase activity.

Ceftizoxime is a bacterial inhibitor which acts by interfering with bacterial cell wall synthesis and inhibiting cross-linking of the peptidoglycan.

Ceftibuten dihydrate is a third-generation cephalosporin antibiotic.

Cefpirome Sulfate is a fourth generation cephalosporin antibiotic.

Cefpiramide sodium (SM-1652; Wy-44635) is a new Pseudomonas-active cephalosporin with a broad spectrum of antibacterial activity.

Cefoxitin is a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity.

Cefmenoxime hydrochloride is a third-generation cephalosporin antibiotic.

Cefetamet pivoxil hydrochloride is an oral third generation cephalosporin antibiotic.

CE-245677 is a potent, selective, orally active, dual Tie2/Trk kinase inhibitor with IC50 of 4.7 nM, 1 nM for Tie2 and TrkA/B, respectively.

CE-224535 (PF-04905428) is a potent and selective P2X7 receptor antagonist with IC50 of 1.4 nM (inhibition of the release of lL-1b from monocytes stimulated by ATP).

CDP-840 (CDP840.

CDP-840 (CDP840.

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection.